Cargando…
Cisplatin induces stemness in ovarian cancer
The mainstay of treatment for ovarian cancer is platinum-based cytotoxic chemotherapy. However, therapeutic resistance and recurrence is a common eventuality for nearly all ovarian cancer patients, resulting in poor median survival. Recurrence is postulated to be driven by a population of self-renew...
Autores principales: | Wiechert, Andrew, Saygin, Caner, Thiagarajan, Praveena S., Rao, Vinay S., Hale, James S., Gupta, Nikhil, Hitomi, Masahiro, Nagaraj, Anil Belur, DiFeo, Analisa, Lathia, Justin D., Reizes, Ofer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058697/ https://www.ncbi.nlm.nih.gov/pubmed/27105520 http://dx.doi.org/10.18632/oncotarget.8852 |
Ejemplares similares
-
CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors
por: Saygin, Caner, et al.
Publicado: (2017) -
miR-181a modulates circadian rhythm in immortalized bone marrow and adipose derived stromal cells and promotes differentiation through the regulation of PER3
por: Knarr, Matthew, et al.
Publicado: (2019) -
Altered glutamine metabolism in platinum resistant ovarian cancer
por: Hudson, Chantelle D., et al.
Publicado: (2016) -
Increased cancer stem cell invasion is mediated by myosin IIB and nuclear translocation
por: Thomas, Dustin, et al.
Publicado: (2016) -
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance
por: Nagaraj, Anil Belur, et al.
Publicado: (2015)